Orforglipron

At a Glance

Classification: Synthetic small-molecule (non-peptide) oral GLP-1 receptor agonist; partial, G protein-biased GLP-1R agonist; anti-obesity and antidiabetic agent

Orforglipron is not a peptide. It is a small molecule that switches on the same receptor as peptide drugs like semaglutide and tirzepatide: the GLP-1 receptor. That is the whole point of it. Peptide GLP-1 drugs are injected, or, in the case of oral semaglutide, taken as a pill with strict fasting rules because the peptide is fragile in the gut. Orforglipron was designed to be a once-daily pill that can be taken with or without food. It was discovered by Chugai Pharmaceutical and licensed to Eli Lilly in 2018. Regulatory status (as of October 2026): • United States: FDA-approved on April 1, 2026 as Foundayo for chronic weight management in adults with obesity, or overweight plus at least one weight-related condition, alongside diet and physical activity. It was the first new molecular entity approved under FDA's Commissioner's National Priority Voucher program. • Type 2 diabetes (U.S.): not an approved U.S. indication as of this writing. Lilly announced plans to submit for type 2 diabetes by the end of Q2 2026. • European Union: on October 15, 2026, EMA's CHMP adopted a positive opinion recommending authorization for both weight management and type 2 diabetes. A final European Commission decision typically follows a CHMP opinion. Orforglipron has one of the largest evidence bases of any compound on Aminodex: Phase 2 and multiple Phase 3 trials (the ATTAIN program for obesity and the ACHIEVE program for type 2 diabetes) involving thousands of participants.

What Is Orforglipron?

Orforglipron is a non-peptide GLP-1 receptor agonist. Native GLP-1 / semaglutide / liraglutide = peptides Orforglipron = small organic molecule. In structural studies, it binds a pocket in the upper part of the GLP-1 receptor, contacting the receptor's extracellular domain and several transmembrane helices. This is a different binding mode from peptide agonists. It acts as a partial agonist that favors G protein signaling over β-arrestin recruitment ("biased agonism"). A notable quirk: orforglipron interacts with a receptor residue found only in primates, so it is not pharmacologically active at rat or mouse GLP-1 receptors. Researchers used mice engineered to carry the human receptor, and monkeys, for preclinical work. This is also why the standard rodent thyroid C-cell tumor findings for GLP-1 drugs could not be tested in the usual way. The U.S. label still carries the class boxed warning about thyroid C-cell tumors.

What Are Researchers Studying?

How Does It Work?

Orforglipron (oral tablet) ↓ absorbed as a small molecule (no peptide-digestion problem) ↓ binds and activates the GLP-1 receptor (partial, G protein-biased agonism) ↓ glucose-dependent insulin release, reduced glucagon, slower gastric emptying, and reduced appetite through brain GLP-1 pathways ↓ lower blood glucose and reduced food intake → weight loss. The effects are those of the GLP-1 class. Common side effects are gastrointestinal (nausea, diarrhea, vomiting, constipation), mostly mild to moderate and most frequent during dose escalation. The FDA label lists class warnings including pancreatitis, gallbladder disease, acute kidney injury from dehydration, hypoglycemia when combined with some diabetes drugs, diabetic retinopathy complications, and aspiration risk under anesthesia.

What Does the Research Show?

Notable Studies

What We Still Don't Know

• Long-term (multi-year) weight maintenance on and after stopping treatment • Effects on hard cardiovascular outcomes (heart attack, stroke, cardiovascular death) beyond safety comparisons • Head-to-head performance against injectable semaglutide 2.4 mg or tirzepatide for obesity • Rare adverse events that appear only with very wide real-world use • Human relevance of GLP-1 class thyroid C-cell findings, which cannot be tested in rodents in the usual way for this drug • Results in adolescents and other populations not yet studied • Whether partial, G protein-biased agonism has meaningful clinical advantages or disadvantages compared with peptide GLP-1 drugs • Final regulatory outcomes for type 2 diabetes in the U.S. and for the EU authorization.

Related Compounds

Sources & References

1. Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A. 2020;117(47):29959–29967.
2. Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes Obes Metab. 2023.
3. Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877–888.
4. Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402(10400):472–483.
5. Rosenstock J, Hsia S, Nevarez Ruiz L, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393(11):1065–1076.
6. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796–1806.
7. Rosenstock J, Yabe D, Cox D, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026.
8. U.S. Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program (Foundayo/orforglipron). April 1, 2026.
9. European Medicines Agency. Foundayo (orforglipron): CHMP summary of opinion, adopted October 15, 2026.
10. Eli Lilly and Company. ACHIEVE-4 topline results press release (planned U.S. type 2 diabetes submission). April 16, 2026.